![]() We were convinced that SARS‑CoV‑2 variants are unlikely to evade theĪntiviral efficacy of Carragelose. “ Given the broad antiviral efficacy and the physical mode of action, Eva Prieschl-Grassauer, Chief Scientific Officer at That show Carragelose inactivates SARS-CoV-2, independent of the “ The COVID-19 pandemic continues to be a major health, social, andĮconomic burden, and we now see variants of SARS-CoV-2 taking over NONS can help get the world back on its feet.” “ The human toll of this disease cannot be expressed simply in numbers,Īnd each day compounds the frustration, fear and loss suffered by Gilly Regev, CEO and co-founder of SaNOtize. The public where it can help bring an end to the pandemic, accelerateĪ return to normality, and prevent future outbreaks of COVID-19 and “ Now that NONS has been demonstrated to be safe and effective inĬlinical trials, we must move with urgency to get it into the hands of The information gathered from SaNOtize’s earlier Phase 2 trials inĬanada and independent lab tests at Utah State University’s Antiviral Infectivity – the frequency of transmission from an infected person to a Treatment in the early stages of infection and for those who have yet toīe vaccinated, NONS has also demonstrated that it could also reduce Long-term care facilities, healthcare and frontline workers, and the Treatment candidate that could soon be widely available at low-cost for The ease of NONS manufacture, storage and use makes NONS a Global production and distribution of vaccines to help keep people safeĪnd healthy. If not years – ahead of full global vaccination.Įquitable global availability of NONS could form a bridge during the Work, school and society, and spur an economic recovery that is months – ![]() Of manufacturing could facilitate an almost immediate safe return to SaNOtize is applying to regulatory authorities in the UKĪnd Canada for Emergency Use authorization. SaNOtize Seeking Emergency Use Authorization in UK and Canada Or Blue Baby Syndrome, in newborn babies. The NO molecule released from NONS is identical to the oneĭelivered in its gaseous form to treat persistent pulmonary hypertension, Toxicity, and safety data for NO use in humans has been well-establishedįor decades. Human body with proven anti-microbial properties shown to have a directĮffect on SARS-CoV-2, the virus that causes COVID-19. It is based on nitric oxide (NO), a natural nanomolecule produced by the Upper airways, preventing it from incubating and spreading to the lungs. The SaNOtize treatment is designed to kill the virus in the Outbreaks and safely reopening economies. Which could be critical in supporting vaccines, preventing future Still demonstrated significant reductions in the levels of SARS-CoV-2, Included patients with a variant of concern and high viral loads yet Treatment of COVID-19 and reducing onward transmission. A significant reduction of viral load in the nasal wash fluids of patients confirmed similar findings from earlier trials in children and adults.Ĭurrent Controlled Trials ISRCTN80148028.“ This simple portable nasal spray could be highly effective in the In adults with common cold virus infections, direct local administration of carrageenan with nasal sprays reduced the duration of cold symptoms. Viral titers in nasal fluids showed a significantly greater decrease in carrageenan patients in the intention-to-treat population (p = 0.024) and in the per protocol population (p = 0.018) between days 1 and 3/4. The primary endpoint that had been prespecified but was changed before unblinding was not met. ![]() In patients showing a laboratory-confirmed cold virus infection and adherence to the protocol, alleviation of symptoms was 2.1 days faster in the carrageenan group in comparison to placebo (p = 0.037). ![]() ![]() During the study, but prior unblinding, the definition of disease duration was adapted from the original protocol that defines disease duration as the time period of symptoms followed by 48 hours without symptoms. The primary endpoint was the duration of disease defined as the time until the last day with symptoms followed by all other days in the study period without symptoms. Application was performed three times daily with either a carrageenan-supplemented nasal spray or saline solution as placebo with an overall observation period of 21 days. In a randomized, double-blind, placebo-controlled trial, 211 patients suffering from early symptoms of the common cold were treated for seven days. This study investigated the efficacy of a carrageenan-containing nasal spray on the duration of the common cold and nasal fluid viral load in adult patients. Iota-carrageenan has previously shown antiviral effectiveness against cold viruses in clinical trials. The common cold is the most widespread viral infection in humans. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |